Endometriosis Boot Camp: Exploring Patient Perspectives to Improve Diagnosis and Management

Program Overview 

Endometriosis is one of the most common benign gynecologic conditions that occur during a woman’s reproductive years. Despite the high prevalence of this disease, a large proportion of women with endometriosis remain undiagnosed and untreated. Unfortunately, even after diagnosis and treatment, recurrent and persistent pain are common and represent a significant challenge for patients and health care providers. Guided by our expert faculty, Endometriosis Boot Camp: Exploring Patient Perspectives to Improve Diagnosis and Management is a multimedia training program designed to strengthen expertise in the diagnosis and treatment of endometriosis.  This activity will provide information on how and when to incorporate diagnostic imaging modalities, weigh the individual risks and benefits of surgical diagnosis and treatment, and incorporate new pharmacologic therapies in the management of endometriosis.

Target Audience 

Educational Objectives  

After completing this activity, the participant should be better able to: 

• Identify how delayed diagnosis contributes to poor quality of life (QOL) for patients with endometriosis, as well as the implications for prognosis and future treatment efficacy
• Examine the roles of imaging, patient history, and physical examination to expedite early clinical diagnosis of endometriosis
• Compare the efficacy and safety profiles of surgery with available pharmacotherapeutics approved to treat endometriosis-related pain and prevent its recurrence
• Individualize diagnosis and treatment strategies for patients with endometriosis, utilizing shared decision-making strategies to reflect patient goals and needs

Physician Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation 

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurse Practitioner Continuing Education 

This activity has been planned and implemented in  accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.1 hour of pharmacology). 

Instructions to Receive Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 70% on the posttest, and complete the program evaluation.

Global Contact Information 

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy 

There is no fee for this educational activity. 

Disclosures of Relevant Financial Relationships 

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated.  

The faculty have the following relevant financial relationships with ineligible companies: 

Sawsan (Suzie) As-Sanie, MD, MPH Consultant: Bayer, Eximis, Myovant Sciences-Pfizer, Organon

Daniel C. Martin, MD Other: Reimbursement of expenses by the Endometriosis Foundation of America education dinner event by Myovant Pharmaceuticals, ASRM 2023

Haley D. (patient): Nothing to disclose

The Global and Integritas Communications planners and managers have nothing to disclose. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.